[12] Patent
[11] Patent No.:GC0004508  
[45] Date of Publishing the Grant of the Patent: 31/Dec /2016                32/2016  
Number of the Decision to Grant the Patent:2016/89343
Date of the Decision to Grant the Patent:11/Dec/2016

[21] Application No.:GC 2013-24413

[22] Filing Date:15/5/2013

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
US
15/5/2012
15/3/2013
61/647,174
61/790,967

[72] Inventors:1- Stephanie Kay Dodd،2- Pascal Furet،3- Robert Martin Grotzfeld،4- Darryl Brynley Jones،5- Paul Manley،6- Andreas Marzinzik،7- Xavier Francois Andre Pelle،8- Bahaa Salem،9- Joseph Schoepfer،10- Wolfgang Jahnke

[73] Owner: Novartis AG, Lichtstrasse 35, Basel 4056, Switzerland

[74] Agent: Saud M. A. Shawwaf Law Office

  

 

  

[51]IPC:
Int. Cl.: A61K 31/4439, 31/506; C07D 213/82, 401/04, 401/14, 405/14 (2006.01)

[56] Cited Documents:

-WO 2004/005281 Al (NOVARTIS AG [CH] ; NOVARTIS PHARMA GMBH [AT]; BREITENSTEI N WERN ER [CH] ;) 15 January 2004
-ECK M J ET AL : The interplay of structural information and functional studies in kinase drug design: insights from BCR-Ab CURRENT OPINION IN CELL BIO LOGY, CURRENT SCI ENCE, LONDON, GB, vol. 21, no. 2, 1 April 2009
 
Examiner: PH. Neda J. AlMuallem

[54] COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1
[57] Abstract: The present invention relates to compounds of formula (I): in which Y, Y1, R1, R2, R3 and R4 are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.
No. of claims: 26     No. of figures: 4


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.